Alvotech to present clinical study data for avt04, a proposed biosimilar to stelara®, at 2023 american academy of dermatology (aad) annual meeting

Alvotech ( nasdaq: alvo ), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the presentation of two posters related to its clinical studies in support of biosimilarity and clinical comparability of alvotech's atv04 (ustekinumab) and the reference product stelara® at the 2023 american academy of dermatology (aad) annual meeting, march 17-21 in new orleans.
ALVO Ratings Summary
ALVO Quant Ranking